Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 2, 2017, Pages 117-124

  Thabit, Hood ^a,b   Hartnell, Sara ^b   Allen, Janet M ^a   Lake, Andrea ^a   Wilinska, Malgorzata E ^a   Ruan, Yue ^a   Evans, Mark L ^a,b   Coll, Anthony P ^a,b   Hovorka, Roman ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN GLARGINE; INSULIN LISPRO;

ADULT; AGED; ARTICLE; ARTIFICIAL PANCREAS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; BLOOD; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INSULIN INFUSION; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED;

EID: 85010607460     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30280-7     Document Type: Article

References (27)

1. 1 Health and Social Care Information Centre (HSCIC), NHS. National diabetes inpatient audit. http://content.digital.nhs.uk/catalogue/PUB20206/nati-diab-inp-audi-15-nat-rep.pdf, 2011 (accessed Oct 27 2016).
2. 2 Wexler, DJ, Meigs, JB, Cagliero, E, Nathan, DM, Grant, RW, Prevalence of hyper- and hypoglycemia among inpatients with diabetes: a national survey of 44 U.S. hospitals. Diabetes Care 30 (2007), 367–369.
3. 3 Umpierrez, GE, Isaacs, SD, Bazargan, N, You, X, Thaler, LM, Kitabchi, AE, Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 87 (2002), 978–982.
4. 4 Dhatariya, K, Should inpatient hyperglycaemia be treated?. BMJ, 346, 2013, f134.
5. 5 Umpierrez, GE, Hellman, R, Korytkowski, MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 97 (2012), 16–38.
6. 6 Thabit, H, Hovorka, R, Glucose control in non-critically ill inpatients with diabetes: towards closed-loop. Diabetes Obes Metab 16 (2014), 500–509.
7. 7 Hovorka, R, Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 7 (2011), 385–395.
8. 8 Thabit, H, Tauschmann, M, Allen, JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 373 (2015), 2129–2140.
9. 9 Kropff, J, Del Favero, S, Place, J, et al. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol 3 (2015), 939–947.
10. 10 Kumareswaran, K, Thabit, H, Leelarathna, L, et al. Feasibility of closed-loop insulin delivery in type 2 diabetes: a randomized controlled study. Diabetes Care 37 (2014), 1198–1203.
11. 11 Evans, S, Day, S, Royston, P, Minim: minimisation program for allocating patients to treatments in clinical trials. http://www-users.york.ac.uk/∼mb55/guide/minimins.doc (accessed Oct 4, 2016).
12. 12 Hovorka, R, Allen, JM, Elleri, D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 375 (2010), 743–751.
13. 13 Hovorka, R, Kumareswaran, K, Harris, J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ, 342, 2011, d1855.
14. 14 Hovorka, R, Nodale, M, Haidar, A, Wilinska, ME, Assessing performance of closed-loop insulin delivery systems by continuous glucose monitoring: drawbacks and way forward. Diabetes Technol Ther 15 (2013), 4–12.
15. 15 Boord, JB, Greevy, RA, Braithwaite, SS, et al. Evaluation of hospital glycemic control at US academic medical centers. J Hosp Med 4 (2009), 35–44.
16. 16 Neubauer, KM, Schaupp, L, Plank, J, et al. Failure to control hyperglycemia in noncritically ill diabetes patients despite standard glycemic management in a hospital setting. J Diabetes Sci Technol 7 (2013), 402–409.
17. 17 Turchin, A, Matheny, ME, Shubina, M, Scanlon, JV, Greenwood, B, Pendergrass, ML, Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 32 (2009), 1153–1157.
18. 18 Ahmann, A, Reduction of hospital costs and length of stay by good control of blood glucose levels. Endocr Pract 10:suppl 2 (2004), 53–56.
19. 19 Ceriello, A, Esposito, K, Piconi, L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57 (2008), 1349–1354.
20. 20 Krinsley, JS, Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med 36 (2008), 3008–3013.
21. 21 Thabit, H, Kumareswaran, K, Haidar, A, et al. Glucose turnover after replacement of usual therapy by insulin in insulin-naive type 2 diabetes subjects. J Clin Endocrinol Metab 99 (2014), 2225–2232.
22. 22 Leelarathna, L, English, SW, Thabit, H, et al. Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial. Crit Care, 17, 2013, R159.
23. 23 Okabayashi, T, Nishimori, I, Maeda, H, Yamashita, K, Yatabe, T, Hanazaki, K, Effect of intensive insulin therapy using a closed-loop glycemic control system in hepatic resection patients: a prospective randomized clinical trial. Diabetes Care 32 (2009), 1425–1427.
24. 24 Okabayashi, T, Shima, Y, Sumiyoshi, T, et al. Intensive versus intermediate glucose control in surgical intensive care unit patients. Diabetes Care 37 (2014), 1516–1524.
25. 25 Mader, JK, Neubauer, KM, Schaupp, L, et al. Efficacy, usability and sequence of operations of a workflow-integrated algorithm for basal-bolus insulin therapy in hospitalized type 2 diabetes patients. Diabetes Obes Metab 16 (2014), 137–146.
26. 26 Abuannadi, M, Kosiborod, M, Riggs, L, et al. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract 19 (2013), 81–90.
27. 27 Umpierrez, GE, Korytkowski, M, Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment. Diabetes Care 36 (2013), 2112–2117.